CMV prevention after lung transplant based on immune status
Part of Lungs & breathing clinical trials.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are scheduled to receive a lung transplant (single or double lung)
- You have tested positive for CMV antibodies (IgG) before transplant
- You are not pregnant or breastfeeding
- You do not have HIV infection
- You are not getting a combined transplant like lung-heart or lung-kidney
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This study looks at how CMV (a common virus) affects the immune system in people who get a kidney transplant or have CMV after transplant. It may help doctors understand and manage CMV better.
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.